These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 22228807)
1. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807 [TBL] [Abstract][Full Text] [Related]
2. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773 [TBL] [Abstract][Full Text] [Related]
3. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328 [TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841 [TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877 [TBL] [Abstract][Full Text] [Related]
7. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024 [TBL] [Abstract][Full Text] [Related]
8. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Chang BY; Huang MM; Francesco M; Chen J; Sokolove J; Magadala P; Robinson WH; Buggy JJ Arthritis Res Ther; 2011 Jul; 13(4):R115. PubMed ID: 21752263 [TBL] [Abstract][Full Text] [Related]
9. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. Konda VR; Desai A; Darland G; Bland JS; Tripp ML Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075 [TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Whang JA; Chang BY Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226 [TBL] [Abstract][Full Text] [Related]
11. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104 [TBL] [Abstract][Full Text] [Related]
12. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. Clark P; Rowland SE; Denis D; Mathieu MC; Stocco R; Poirier H; Burch J; Han Y; Audoly L; Therien AG; Xu D J Pharmacol Exp Ther; 2008 May; 325(2):425-34. PubMed ID: 18287210 [TBL] [Abstract][Full Text] [Related]
13. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693 [TBL] [Abstract][Full Text] [Related]
14. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Hartkamp LM; Fine JS; van Es IE; Tang MW; Smith M; Woods J; Narula S; DeMartino J; Tak PP; Reedquist KA Ann Rheum Dis; 2015 Aug; 74(8):1603-11. PubMed ID: 24764451 [TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase. Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202 [TBL] [Abstract][Full Text] [Related]
17. Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Malaviya R; Uckun FM Biochem Biophys Res Commun; 1999 Apr; 257(3):807-13. PubMed ID: 10208864 [TBL] [Abstract][Full Text] [Related]
18. Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. Phillips JE; Renteria L; Burns L; Harris P; Peng R; Bauer CM; Laine D; Stevenson CS J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):233-41. PubMed ID: 27111445 [TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680 [TBL] [Abstract][Full Text] [Related]
20. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]